Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Stock Information for RiceBran Technologies

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RiceBran Technologies

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 - 25, 2025
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.